Tandem Diabetes Care, Inc. (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.
The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends. Tandem also offers the t:flex® Insulin Pump for users requiring higher insulin volumes and provides a cloud-based data management platform, t:connect®, which enables patients and healthcare providers to review pump and sensor data for more informed treatment decisions.
Tandem Diabetes Care primarily serves the U.S. market under FDA clearance and, through CE Mark authorization, has expanded distribution into Europe. The company has also secured regulatory approvals and established commercial partnerships in Canada and other select international markets. Its customer base includes adults and children with type 1 diabetes as well as insulin-requiring patients with type 2 diabetes.
Under the leadership of President and Chief Executive Officer Kim Blickenstaff and supported by Chief Financial Officer John Sheridan, Tandem Diabetes Care continues to invest in product innovation, clinical research and digital health solutions. The company’s mission is to simplify diabetes management, improve patient outcomes and drive broader adoption of advanced insulin delivery technologies.
AI Generated. May Contain Errors.
